Advanced

Dyskinesia matters

Cenci, M. Angela LU ; Riggare, Sara ; Pahwa, Rajesh ; Eidelberg, David and Hauser, Robert A. (2019) In Movement Disorders
Abstract

Levodopa-induced dyskinesia (LID) represents a significant source of discomfort for people with Parkinson's disease (PD). It negatively affects quality of life, it is associated with both motor and nonmotor fluctuations, and it brings an increased risk of disability, balance problems, and falls. Although the prevalence of severe LID appears to be lower than in previous eras (likely owing to a more conservative use of oral levodopa), we have not yet found a way to prevent the development of this complication. Advanced surgical therapies, such as deep brain stimulation, ameliorate LID, but only a minority of PD patients qualify for these interventions. Although some have argued that PD patients would rather be ON with dyskinesia than OFF,... (More)

Levodopa-induced dyskinesia (LID) represents a significant source of discomfort for people with Parkinson's disease (PD). It negatively affects quality of life, it is associated with both motor and nonmotor fluctuations, and it brings an increased risk of disability, balance problems, and falls. Although the prevalence of severe LID appears to be lower than in previous eras (likely owing to a more conservative use of oral levodopa), we have not yet found a way to prevent the development of this complication. Advanced surgical therapies, such as deep brain stimulation, ameliorate LID, but only a minority of PD patients qualify for these interventions. Although some have argued that PD patients would rather be ON with dyskinesia than OFF, the deeper truth is that patients would very much prefer to be ON without dyskinesia. As researchers and clinicians, we should aspire to make that goal a reality. To this end, translational research on LID is to be encouraged and persistently pursued.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
animal models, basal ganglia, drug development, pathophysiology, therapy complications
in
Movement Disorders
publisher
John Wiley & Sons
external identifiers
  • pmid:31872501
  • scopus:85077145241
ISSN
0885-3185
DOI
10.1002/mds.27959
language
English
LU publication?
yes
id
431b19ef-08c6-4b7a-95c6-2da60d8cac13
date added to LUP
2020-01-17 12:05:12
date last changed
2020-02-23 08:07:32
@article{431b19ef-08c6-4b7a-95c6-2da60d8cac13,
  abstract     = {<p>Levodopa-induced dyskinesia (LID) represents a significant source of discomfort for people with Parkinson's disease (PD). It negatively affects quality of life, it is associated with both motor and nonmotor fluctuations, and it brings an increased risk of disability, balance problems, and falls. Although the prevalence of severe LID appears to be lower than in previous eras (likely owing to a more conservative use of oral levodopa), we have not yet found a way to prevent the development of this complication. Advanced surgical therapies, such as deep brain stimulation, ameliorate LID, but only a minority of PD patients qualify for these interventions. Although some have argued that PD patients would rather be ON with dyskinesia than OFF, the deeper truth is that patients would very much prefer to be ON without dyskinesia. As researchers and clinicians, we should aspire to make that goal a reality. To this end, translational research on LID is to be encouraged and persistently pursued.</p>},
  author       = {Cenci, M. Angela and Riggare, Sara and Pahwa, Rajesh and Eidelberg, David and Hauser, Robert A.},
  issn         = {0885-3185},
  language     = {eng},
  publisher    = {John Wiley & Sons},
  series       = {Movement Disorders},
  title        = {Dyskinesia matters},
  url          = {http://dx.doi.org/10.1002/mds.27959},
  doi          = {10.1002/mds.27959},
  year         = {2019},
}